Abhishek Maiti Selected Research

venetoclax

4/2024	Molecular responses in decitabine- and decitabine/venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes.
12/2023	Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax.
11/2023	Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia.
1/2023	Triple combination targeting methyltransferase, BCL-2, and PD-1 facilitates antileukemia responses in acute myeloid leukemia.
1/2023	Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation.
11/2022	Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.
10/2022	Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies.
5/2022	Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study.
1/2022	Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML.
1/2022	How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Abhishek Maiti Research Topics

Disease

35	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/2024 - 12/2016
9	Neoplasms (Cancer) 03/2024 - 01/2017
8	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 04/2024 - 01/2019
5	Leukemia 02/2024 - 02/2019
4	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2023 - 01/2018
4	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2021 - 01/2017
3	Infections 01/2022 - 09/2018
3	Thrombocytopenia (Thrombopenia) 01/2021 - 01/2016
3	Blast Crisis (Blast Phase) 01/2021 - 01/2017
2	Lymphoma (Lymphomas) 07/2022 - 01/2021
2	Cytopenia 01/2022 - 01/2021
2	Philadelphia Chromosome 01/2021 - 01/2020
2	Neutropenia 01/2021 - 02/2019
2	Myeloid Leukemia (Leukemia, Myelocytic) 01/2020 - 02/2019
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2020 - 09/2018
2	Sarcoma (Soft Tissue Sarcoma) 02/2019 - 04/2016
2	Renal Cell Carcinoma (Grawitz Tumor) 08/2017 - 04/2016
1	Graft vs Host Disease (Graft-Versus-Host Disease) 02/2024
1	Bites and Stings (Sting) 04/2023
1	Cytokine Release Syndrome 01/2023
1	Multiple Myeloma 01/2023
1	Hematologic Neoplasms (Hematological Malignancy) 01/2023
1	Invasive Fungal Infections 10/2022
1	Hydroa Vacciniforme 07/2022
1	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 07/2022
1	Exanthema (Rash) 01/2021
1	Tumor Lysis Syndrome 01/2021
1	Thymoma (Thymic Carcinoma) 06/2019
1	Aplastic Anemia (Anemia, Hypoplastic) 06/2019
1	Acquired amegakaryocytic thrombocytopenia 06/2019
1	Anemia 02/2019
1	Disease Resistance 01/2019
1	Carcinosarcoma 01/2019
1	Sepsis (Septicemia) 01/2019
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2019

Drug/Important Bio-Agent (IBA)

27	venetoclaxIBA 04/2024 - 01/2018
9	Decitabine FDA Link 04/2024 - 01/2021
5	Azacitidine (5 Azacytidine)FDA Link 01/2023 - 01/2017
3	Tyrosine Kinase InhibitorsIBA 01/2021 - 01/2017
2	enasidenibIBA 01/2023 - 01/2022
2	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 02/2019
2	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2023 - 11/2022
2	Cytarabine (Cytosar-U)FDA LinkGeneric 05/2022 - 09/2017
2	ibrutinibIBA 01/2020 - 09/2018
2	Gemcitabine FDA Link 01/2019 - 08/2017
1	Phospholipids (Phosphatides)FDA LinkGeneric 03/2024
1	Lipid Bilayers (Lipid Bilayer)IBA 03/2024
1	RNA Splicing FactorsIBA 11/2023
1	midostaurinIBA 04/2023
1	gilteritinibIBA 04/2023
1	c-Mer Tyrosine KinaseIBA 04/2023
1	Chimeric Antigen ReceptorsIBA 01/2023
1	Bispecific AntibodiesIBA 01/2023
1	daratumumabIBA 01/2023
1	EnzymesIBA 01/2023
1	NucleophosminIBA 01/2023
1	Programmed Cell Death 1 ReceptorIBA 01/2023
1	NivolumabIBA 01/2023
1	MethyltransferasesIBA 01/2023
1	AntibodiesIBA 01/2023
1	EpitopesIBA 01/2023
1	TriazolesIBA 10/2022
1	Dapsone FDA Link 07/2022
1	romidepsin (FK228)FDA Link 07/2022
1	Thalidomide (Thalomid)FDA Link 07/2022
1	Methotrexate (Mexate)FDA LinkGeneric 07/2022
1	Prednisone (Sone)FDA LinkGeneric 07/2022
1	Mycophenolic Acid (Cellcept)FDA LinkGeneric 07/2022
1	purineIBA 05/2022
1	AnthracyclinesIBA 05/2022
1	trametinibIBA 01/2022
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2022
1	Mechanistic Target of Rapamycin Complex 1IBA 11/2021
1	bosutinibIBA 01/2021
1	AzolesIBA 01/2021
1	Inotuzumab OzogamicinIBA 01/2021
1	nelarabine (506U78)FDA Link 01/2021
1	bcr-abl Fusion ProteinsIBA 01/2020
1	Dasatinib (BMS 354825)FDA Link 01/2020
1	CR 6IBA 01/2020
1	PM 01183IBA 02/2019
1	TrabectedinIBA 02/2019
1	CreatinineIBA 02/2019
1	binimetinibIBA 01/2019
1	eculizumab FDA Link 01/2019
1	Docetaxel (Taxotere)FDA Link 01/2019
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2019
1	Phosphotransferases (Kinase)IBA 01/2019
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2019
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2019
1	MitogensIBA 01/2019
1	Proteins (Proteins, Gene)FDA Link 01/2019

Therapy/Procedure

20	Therapeutics 03/2024 - 01/2017
17	Drug Therapy (Chemotherapy) 12/2023 - 04/2016
2	Hematopoietic Stem Cell Transplantation 02/2024 - 01/2023
2	Induction Chemotherapy 01/2022 - 12/2016
2	Adjuvant Chemotherapy 04/2016 - 01/2013
1	Remission Induction 10/2022
1	Drug Tapering 01/2022
1	Stem Cell Transplantation 06/2019